Currently, LDL is the primary target for assessing and treating atherosclerotic cardiovascular disease (ASCVD) risk, whereas non-HDL-C or apolipoprotein B (Apo B) are considered secondary targets [26, 27]. This evidence concerns the gene APOB and atherosclerosis.